Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Blood Test Can Predict Heart Attack Risk within Six Months

By LabMedica International staff writers
Posted on 13 Feb 2024

Heart attacks are the leading cause of death globally, with their incidence on the rise. More...

Despite this, many high-risk individuals either remain unidentified or fail to adhere to preventive treatments. Notably, the period preceding a heart attack is marked by significant biological changes. For instance, the risk of a heart attack doubles in the month following a divorce and increases fivefold in the week after a cancer diagnosis. Based on the hypothesis that several vital biological processes are active during the months before a heart attack, researchers have now suggested that these could be detected using a simple blood test.

Researchers at Uppsala University (Uppsala, Sweden) have developed an online tool that, when used in conjunction with standard blood test results, can help clinicians determine if a person is at an elevated risk of experiencing a heart attack within the next six months. The study involved analyzing blood samples from 169,053 individuals from six European cohorts who had no previous history of cardiovascular disease. Of these participants, 420 suffered their first heart attack within six months. Their blood samples were then compared with those from 1,598 healthy cohort members.

The research team identified approximately 90 molecules associated with an increased risk of a first heart attack. Interestingly, existing healthcare blood samples are sufficient to predict this risk. The research team plans to further explore these 90 newly identified molecules to better understand them and investigate potential treatment opportunities. Additionally, the online tool created by the researchers enables individuals to assess their six-month heart attack risk. This tool is intended to boost patients' motivation to adopt healthier lifestyles, such as adhering to preventive medication regimens or quitting smoking.

“We wanted to develop methods that would enable the health services to identify people who will soon suffer their first heart attack,” said Professor Johan Sundström at Uppsala University who led the research team. 

Related Links:
Uppsala University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.